Article, Early Access,
Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity
Affiliations
- [1] Univ N Carolina, Dept Med, Div Endocrinol & Metab, Sch Med, Campus Box 7172,8072 Burnett Womack,160 Dent Circl, Chapel Hill, NC 27599 USA [NORA names: United States; America, North; OECD];
- [2] Univ N Carolina, Dept Med, Div Endocrinol & Metab, Sch Med, Campus Box 7172,8072 Burnett Womack,160 Dent Circl, Chapel Hill, NC 27599 USA [NORA names: United States; America, North; OECD];
- [3] Univ N Carolina, Dept Med, Div Endocrinol & Metab, Sch Med, Campus Box 7172,8072 Burnett Womack,160 Dent Circl, Chapel Hill, NC 27599 USA [NORA names: United States; America, North; OECD];
- [4] Novo Nordisk AS, Soborg, Denmark [NORA names: Novo Nordisk; Private Research; Denmark; Europe, EU; Nordic; OECD];
- [5] Johns Hopkins Univ, Ctr Drug Safety & Effectiveness, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA [NORA names: United States; America, North; OECD];
(... more)
Abstract
Abstract not displayed. As this article is not marked as Open Access, it is unclear if we are allowed to show the abstract. Please use the link in the sidebar to view the data provider version of the article including abstract.
Keywords
COVID-19,
GLP-1RA,
National COVID Cohort Collaborative (N3C),
Observational data,
SARS-CoV-2,
SGLT-2i,
Type 2 diabetes